Abstract Asthma, allergic rhinitis (AR) and atopic dermatitis also called eczema are allergic co-morbidites, which are likely to depend on pleiotropic genetic effects as well as on specific genetic factors. After a previous genome-wide linkage screen conducted for asthma and AR in a sample of 295 French EGEA families ascertained through asthmatic subjects, the aim here was to search for genetic factors involved in eczema and more particularly the ones shared by the three allergic diseases using the same EGEA data. In this sake, eczema and phenotypes of ''allergic disease'' accounting for the joint information on the presence/absence of the three diseases were examined by
Introduction
Pleiotropy is likely to play an important role in the genetic determinism of multifactorial diseases as shown by genome-wide linkage screens (Kullo et al. 2005; Marlow et al. 2003; Williams et al. 1999 ) and recent genome-wide association studies of complex disorders [The Wellcome Trust Case Control Consortium (WTCCC) 2007] . Asthma, allergic rhinitis (AR) and atopic dermatitis (AD) also called eczema are allergic co-morbidites, which may share genetic determinants as suggested by their strong associations at both the individual and familial levels (Dold et al. 1992) . Genes with pleiotropic effects underlying these three diseases may be involved in allergic processes or in the barrier mechanisms of the epithelium (of either the skin, the nose or the lung). However, there may also be genes specific to two of the three diseases, e.g. specific to the airway organs such as nose and lung, or specific to each of the three diseases.
Few genome-wide searches have been conducted for AR (Haagerup et al. 2001; Yokouchi et al. 2002; Dizier et al. 2005; Bu et al. 2005) and AD (Lee et al. 2000; Cookson et al. 2001; Bradley et al. 2002; Haagerup et al. 2004) contrasting with the numerous genome screens performed for asthma and asthma-associated phenotypes (Wills-Karp and Ewart 2004; Bouzigon et al. 2005) . These scans have revealed a small number of regions potentially linked to two or three of those diseases but none of them as yet examined these diseases jointly. Candidate gene studies have reported a few genes associated with at least two of these diseases including genes involved in the allergic response such as TLR2 (4q31.3) (Ahmad-Nejad et al. 2004 ), IL-13 (5q31) (Tsunemi et al. 2002; He et al. 2003; Liu et al. 2000) , FCER1B (11q12) (Folster-Holst et al. 1998; Cox et al. 1998), TGFB1 (19q13) (Arkwright et al. 2001 ) and CCL5 (17q11) , indicating pleiotropic effect of these genes.
The epidemiological study on the genetics and environment of asthma (EGEA) was designed to characterize genes and environmental factors underlying asthma-related phenotypes in families ascertained through asthmatic subjects. This study includes extensive information on various biological and physiological phenotypes as well as asthma-associated diseases such as AR and eczema. Genome scans (GS) were recently carried out in the 295 EGEA family sample for seven asthma/atopy-associated phenotypes (Bouzigon et al. 2004 ) and for asthma and AR (Dizier et al. 2005) . Joint analysis of asthma and AR showed strong evidence for a genetic component on the 1p31 region underlying the co-morbidity of asthma plus AR (Dizier et al. 2007 ). Our present aim was to complete these scans by searching for genetic regions linked to eczema and more precisely to characterize the regions shared by eczema and the two other allergic diseases, asthma and AR. For this purpose, we considered an ''allergic disease'' phenotype which was defined in two ways: (1) by the presence of at least one of the allergic diseases (asthma, AR and eczema) and (2) using an ordered categorical trait varying from 0 to 3 depending on the number of allergic diseases presented by a subject. The genome-wide linkage analyses for eczema and ''allergic disease'' phenotypes were conducted in the sample of 295 EGEA families using the original panel of 378 microsatellites. In regions showing an indication of linkage, we conducted fine mapping (FM) and association studies in the vicinity of the linkage peaks. The present study is the first genome linkage scan examining jointly asthma, AR and eczema to search for pleiotropic genes involved in these three diseases.
Materials and methods

Family data
The main EGEA sample included 348 nuclear families selected through one asthmatic proband. An additional sample of 40 nuclear families was selected through two asthmatic sibs in order to increase the number of informative families for linkage analyses of asthma. Inclusion criteria met by the probands were described elsewhere (Kauffmann et al. 1999 ). The present scan was applied to 307 EGEA families having at least two sibs with DNA available (Bouzigon et al. 2004) . After excluding families with insufficient DNA available or showing non-Mendelian transmission, the analyzed sample included 295 families (n = 1,317 individuals). Ethical committee of the hospital group ''Cochin Saint Vincent de Paul-Sainte Anne'' approved the protocol and subjects signed informed consent forms.
Phenotypes analyzed
Information on respiratory and allergic symptoms, medical history and environmental factors was collected using a standardized questionnaire (Kauffmann et al. 2002) . Various physiological tests were performed, which have been already described (Kauffmann et al. 1999 ) and included bronchial responsiveness and skin prick tests to common aeroallergens.
Eczema was defined by answers to a questionnaire in adults and children. For children, the questions asked to the child's mother (or father) were: (1a) Have your child had eczema before 2 years of age? and (2a) After 2 years of age? and for adults: (1b) Have you had eczema during childhood? The precise time of eczema onset (before/after 2 years of age) was not asked to adults in order to avoid a large proportion of wrong or missing responses. Two definitions of eczema were possible: (1) a positive response to 1a for children and 1b for adults, (2) a positive response to 1a or 2a for children and 1b for adults. We used here only the second definition since it has the advantage to be homogenous in children and adults. The high frequency of atopy defined by a positive skin test response to at least one allergen in both children and adults reporting eczema strengthened the validity of our eczema definition.
Definitions of asthma and AR used in linkage analyses of the ''allergic disease'' phenotype have been previously described (Dizier et al. 2005 (Dizier et al. , 2007 . Asthma (AST) was defined using the following criteria: a positive response to at least one of the two questions: (1) Have you ever had attacks of breathlessness at rest with wheezing? (2) Have you ever had an asthma attack?, associated with either the presence of BHR (defined as a fall in baseline FEV 1 , the forced expiratory volume in 1 s, ‡20% at £4 mg/ml methacholine), an increase of baseline FEV 1 ‡ 12% after bronchodilator use, hospitalization for asthma in life or asthma therapy. The AR trait was defined by the presence of at least one of the following symptoms: sneezing or runny nose to hay/flower or animals or dust.
The ''allergic disease'' phenotype was defined in two ways (1) by the presence of at least one of the three allergic diseases (ECZ ± AST ± AR), and that, whatever the disease(s) was, (2) using an ordered categorical trait varying from 0 to 3 depending on the number of allergic diseases presented by a subject.
Genotypes
A total of 1,317 subjects were genotyped with a panel of 396 microsatellites (378 autosomal markers). The genotyping protocol was described elsewhere (Bouzigon et al. 2004; Dizier et al. 2005) . The Linkage Marker Set MD 10 (Applied Biosystems, Foster City, CA, USA) formed the core marker set for the genome-wide screen. The microsatellite markers, labeled with fluorescent dyes (FAM TM , HEX TM , NED TM ), are distributed at an average marker density of 10 centimorgan ([cM] roughly every 10 million bases in the genome) and have an average heterozygosity of 75%.
Before statistical analysis, rigorous genotype quality assurance was performed to ensure accurate binding of alleles. In the four regions detected potentially linked to eczema and/or to the ''allergic disease'' phenotype(s), FM was carried out by genotyping additional markers in an interval spanning about 10 cM on each side of the linkage peaks: two markers on 5p15, three markers on 5q13, eight markers on 11p14-q13 and four markers on 17q21.
Consistency of the data with Mendelian inheritance and presence of double recombination between loci was evaluated using Pedcheck (O'Connell and Weeks 1998) and Mendel (Lange et al. 2001 ). Hardy-Weinberg equilibrium was also checked for all markers.
Linkage analysis methods
Linkage analyses were performed by a model-free approach, the maximum likelihood binomial (MLB) method which is likelihood-based and can be applied to the whole sibship of affected subjects (Majumder and Pal 1987; Satsangi et al. 1996; . In brief, the principle of this method is based on the binomial distribution of the number of affected sibs receiving a given parental allele from heterozygous parents. The probability a for an affected sib to receive from his/her parent the marker allele transmitted with the disease allele is equal to 0.5 under the null hypothesis of no linkage and a is greater than 0.5 under the hypothesis of linkage. Test for linkage was performed using a likelihood ratio test statistic, K = 2Ln[L(a)/L(a = 0.5)] with the statistic K being distributed asymptotically as a mixture distribution of 0.5v 2 0 df and 0.5v 2 1 df . The test can also be expressed either as a onesided standard normal deviate denoted as Z MLB = K ½ or as a LOD score criterion, LOD MLB = K/(2Ln (10)). This method has been extended to categorical traits by introducing a latent binary variable (Y = {0;1}) which captures the linkage information between the observed categorical phenotype (Z) and the marker (M). This method requires assigning the probability of the latent variable (i.e. being affected or not) according to each observed category of the phenotype (Alcais et al. 1999) . The likelihood of the observations is then written by the use of binomial distributions of parental marker alleles among offspring according to the value of the unobserved binary variable. Multipoint linkage analyses of binary and polychotomous phenotypes were conducted with MLBGH (Abel and Muller-Myhsok 1998) which incorporates the MLB method into the multipoint approach of Genehunter (Kruglyak et al. 1996) .
Family-based association test
Association studies were performed using the family-based association test (FBAT) method , which is based on the following score S i for n i offspring in the ith family: S i ¼ P j¼1;n i X ij T ij where T ij is a function of jth offspring phenotype and X ij a function of jth offspring genotype in family i. The standard choice, as classically used by the TDT (Spielman and Ewens 1998) is to let T ij = 1 for affecteds and T ij = 0 for unaffecteds and X ij be the number of A alleles (additive coding). We used the standard coding for T ij and both the multi-allelic and additive codings for X ij . When considering the additive coding (i.e. testing alternatively one allele against all the other ones), [S -E(S)]/HVar(S) follows a v 2 with one degree of freedom while for the multi-allelic coding, the statistic (S -E(S)) 0 Var(S) -1 (S -E(S)) has an approximate v 2 distribution with degrees of freedom equal to the number of alleles minus one. This method was applied to test the association in the presence of linkage. We also used the approach by using the empirical variance-covariance estimator, which is robust to the correlation among sibling marker genotypes (Lake et al. 2000) . The FBAT was conducted for all genotyped microsatellites in all regions detected by the MLB approach.
Results
Distribution of eczema and ''allergic disease''
Among the 726 genotyped siblings of the 295 EGEA families selected through one asthmatic subject, frequencies of sibs with eczema and ''allergic disease'' (ECZ ± AST ± AR) were equal to 33 and 72%, respectively (Table 1) . These frequencies did not differ according to the gender for eczema (p = 0.77) but were significantly higher in males than in females for ''allergic disease'' (p = 0.01). Mean ages among siblings with eczema and with ''allergic disease'' were 14.3 and 15.8 years, respectively. The proportion of sibs with asthma and AR among those having eczema and the distribution of asthma, eczema and AR among sibs with ''allergic disease'' are also given in Table 1 . We also examined the percentage of atopy or SPT (defined by a positive skin test response to at least one allergen) in siblings with eczema and ''allergic disease''. Frequencies of asthma, AR and SPT among sibs with eczema were equal to 71, 52 and 77%, respectively. Among siblings having ''allergic disease'', frequencies of eczema, asthma, AR and SPT were equal to 46, 77, 62 and 78%, respectively. The proportion of siblings with ''allergic disease'' having all the three diseases (ECZ + AST + AR) is as high as 20%, demonstrating the strong relationship among these diseases. However, these frequencies may be partly explained by the ascertainment of our sample through asthmatic subjects. Considering the ''allergic disease'' phenotype defined by the ordered categorical trait, the numbers of siblings with 0, 1, 2 or 3 disease(s) were 207, 197, 218 or 104. The distributions of the 295 EGEA families according to the number of genotyped sibs available for linkage analysis of eczema and ''allergic disease'' phenotypes are shown in Table 2 . To provide a summary indicator of the amount of information available for linkage analysis, the number of independent sib-pairs computed from sibship sizes (a sibship of size n corresponds to (n -1) independent sib-pairs) are also given in Table 2 . In parentheses are the corresponding numbers of affected sib-pairs a ''Allergic disease'' phenotype defined by the presence of at least one the 3 allergic diseases (asthma, AR, eczema) b ''Allergic disease'' phenotype defined by the ordered categorical trait varying from 0 to 3 depending on the number of allergic diseases presented by a subject
Linkage analysis
Linkage peaks (expressed in terms of LOD-MLB scores) detected at p £ 0.005 are presented in Tables 3 (eczema) and 4 (ECZ ± AST ± AR). LOD-MLB curves for chromosomes harboring these peaks are shown in Figs. 1 (eczema) and 2 (ECZ ± AST ± AR). The information content (IC), which measures the informativity of the data for linkage analysis, was also given at each marker position on these figures. For eczema, one region, 5q13, showed a linkage peak with p = 0.002 and another one, 11p14, contained a peak with p = 0.0007. Interestingly, the ''allergic disease'' phenotype (ECZ ± AST ± AR) was also found to be linked to the 11p14 region (p = 0.0005). Two other regions were revealed: 5p15 (p = 0.002) and 17q21 (p = 0.003). When analyzing the ''allergic disease'' phenotype defined by the ordered categorical trait, a linkage peak was also detected in the 11p14 region, but with a smaller intensity (p = 0.01). No other region was detected (results not shown).
As shown in Fig. 1 , FM, conducted in the two regions potentially linked to eczema, led to an increase in evidence of linkage for eczema on both 5q13 (p = 0.0007) and 11p14 (p = 0.00005). However, the FM did not change much the linkage results on 5p15, 11p14 and 17q21 for the ''allergic disease'' phenotype (ECZ ± AST ± AR) ( Table 4) .
Family-based association analyses
Family-based association test analysis did not indicate any linkage/association to eczema (i.e. no result leading to a p value £ 0.005) in any region detected by the MLB method. In contrast, evidence for linkage and association was found between ''allergic disease'' (ECZ ± AST ± AR) and D11S4152 marker located on 11p14 region (p = 0.004 and 0.05 using FBAT without and with the empirical variance/covariance estimator, respectively) at the same position as the MLB linkage peak.
Discussion
The present genome-wide scan is the first one searching the existence of genetic determinants predisposing to any of the three diseases, asthma, AR and eczema. It also allowed making comparisons of the linkage signals detected here for eczema to those previously reported for asthma and AR in the same families (Dizier et al. 2005 ). Concerning eczema, there is a strong linkage signal with the 11p14 region. Evidence for linkage to this region was further supported by the FM with an improvement of the linkage signal (p value decreasing from p = 0.0007 to 5 · 10 -5 ). Indication of linkage is also showed for another region 5q13. While 5q13 was not previously detected for asthma or AR in the EGEA study, there was in the 11p14 region a small linkage signal for the two diseases. No linkage signal was detected for eczema to regions reported in our previous scans conducted for AR and/or asthma (1p31, 2q32, (Dizier et al. 2005) . A strong linkage signal of the 11p14 region was also observed with the ''allergic disease'' phenotype defined by the presence of at least one allergic disease. Moreover, an association found between this phenotype and a marker on 11p14 region, located at the linkage peak, strengthened this linkage result. Two additional regions, 5p15 and 17q21, were also detected for linkage to ''allergic disease'', but with a smaller intensity. None of the regions detected by the previous GS conducted for AD (Lee et al. 2000; Cookson et al. 2001; Bradley et al. 2002; Haagerup et al. 2004 ) was found by the present analysis. However, reported results were already heterogeneous across the four previous published AD/ eczema GS. Heterogeneity of results could be due to different modes of family ascertainment, phenotype definitions and linkage analysis statistics. There was indeed heterogeneity regarding the mode of ascertainment, since eczema family samples in previous scans were recruited through one or two affected siblings while the present sample consisted of families with at least two affected siblings, selected from the primary sample of 295 EGEA families ascertained through asthmatic subjects. Interestingly, the Swedish and Danish studies (Bradley et al. 2002; Haagerup et al. 2004) showing the most similar results (3p and 18q detected by both scans) used the most similar phenotype definitions (clinical characteristics associated with elevated specific IgE levels to at least one allergen). Note also, that we used here, responses to diagnosis questions on eczema and not presence of clinical symptoms or presence of atopy. However, most siblings with eczema in our sample were atopic (77%). We repeated linkage analyses by examining eczema associated with a positive skin test response to at least one allergen, as also recommended by the Nomenclature Review Committee of the World Allergy Organisation (2003) (Johansson et al. 2004 ).
This did not lead to detect neither any of the regions found in the Swedish and Danish scans (Bradley et al. 2002; Haagerup et al. 2004 ) nor regions reported by any other scans (data not shown). However, the 11p14 region was still detected although in a slightly lesser extent (p = 0.001), probably because of the important decrease in the number of affected sibs. Some siblings may have been discarded since the tested allergens did not include food allergens. It has indeed been shown that, early in life, eczema is marked by a much higher frequency of food sensitization than aeroallergen sensitization (Guillet and Guillet 1992) . Moreover, a transient form of eczema without any detectable IgE sensitization has been described in children, which develop a sensitization to aeroallergens and to food allergens later in life (Novembre et al. 2001) . We also repeated linkage analyses by considering as an additional criterion for eczema, an age at onset before 2 years of age for the children. That is considered as a good indicator of the presence of atopic eczema. This information being not available for adults, the criterion was thus unchanged for adults, i.e. an onset during childhood. These analyses led to an evidence of linkage as strong as the one with the eczema phenotype used here and allowed us to check our findings with the 11p14 region.
One main topic of our study was to search for pleiotropic effect between the allergic diseases. In this sake, we previously examined eczema associated with either asthma or AR (as already done for asthma associated with AR), but there was no improvement of any linkage signal (result not shown). Moreover, it was not possible to analyze the most stringent phenotype of eczema associated with both asthma and AR because of the too small number of affected sibs. In the same spirit, we then examined the ''allergic disease'' phenotypes. Linkage analysis of the ''allergic disease'' phenotype defined by the presence of any of the three diseases, revealed a strong linkage signal to 11p14. This latter result might be partly explained by the strong evidence of linkage of this region to eczema and by the linkage signals to AR (p = 0.01) and asthma (p = 0.02). When using the other ''allergic disease'' phenotype defined by an ordered categorical trait, a linkage signal although of small magnitude, was also found in the 11p14 region. These different results could suggest that a genetic factor in the 11p14 region is involved more likely in the presence/absence of the allergic disease than in the intensity of the disease measured by the ordered categorical trait, i.e. the number of allergic disease(s) presented by the subject. Finally, the family sampling through asthmatic subjects might have affected the conclusions of our analyses by leading to detect preferentially genes involved in both eczema and asthma (i.e. with pleiotropic effect). Indeed most sib-pairs with eczema were also asthmatic. That could explain why the 11p14 region founded here was linked to both eczema and ''allergic disease''. Regions found in our study linked to eczema and/or to ''allergic disease'' have been previously reported by EGEA scans for other phenotypes and/or by other GS for asthma and asthma-related phenotypes. The 5q13 region potentially linked here to eczema and to ''allergic disease'' was reported by a Danish scan (Haagerup et al. 2001 ) that showed a small linkage signal to AR. The 11p14 region detected here to be linked to eczema and ''allergic disease'' was reported for atopy and asthma-related phenotypes in some studies (Wjst et al. 1999; Altmuller et al. 2005; Ober et al. 2000; Postma et al. 2005; Ferreira et al. 2006) . Note that there was no indication of linkage of this region, neither to IgE nor to SPT, but only an indication of linkage to AR and asthma in the whole EGEA sample (Dizier et al. 2005) and to IgE in a subset of families with at least 2 two asthmatic sibs (Dizier et al. 2000) . The 17q21 region, found here potentially linked to ''allergic disease'', indicated linkage to atopy in the EGEA families (Bouzigon et al. 2004) and was reported to be linked to atopy and asthmarelated phenotypes by other scans [Collaborative Study on the Genetics of Asthma (CSGA) 1997; Koppelman et al. 2002] . This region contains a few candidate genes shown to be associated to AD and which are involved in the immune response as SCYA5 and RANTES . Finally, the 5p15 region suggesting linkage to ''allergic disease'' indicated linkage to atopy in EGEA families (Bouzigon et al. 2004) , to BHR in the Hutterites (Ober et al. 2000) , to asthma in Afro-American CSGA families (1997) and to AD in the Swedish families (Bradley et al. 2002) . We chose here a quite stringent threshold (p £ 0.005) to select linked regions, because of the increase of type one error due to multiple testing. As in the vast majority of published scans for asthma, none of our results reached the genome-wide significant level (p £ 2 · 10 -5 ) proposed by (Lander and Kruglyak 1995) , although LOD scores in the 11p14 region reached the criterion of suggestive linkage (p £ 7 · 10 -4 ) (Lander and Kruglyak 1995) . Evidence for linkage to 11p14 was further supported by the FM that led to a strong improvement of the linkage signal (p value decreasing from p = 0.0007 to 5 · 10 -5 ), the former signal being close to the genome-wide significant level (Lander and Kruglyak 1995) .
In conclusion, evidence of linkage of 11p14 to eczema and ''allergic disease'' was here well supported. Moreover, the association found between the ''allergic disease'' phenotype and a marker located at the ''allergic disease'' linkage peak in the 11p14 region, strengthened the linkage results and suggested that a gene with a pleiotropic effect tightly linked to that peak, may be involved in the allergic diseases. However, whether the 11p14 region contains one or more genetic factor(s) require further investigation. Association studies with SNPs covering this region and with candidate genes involved in the allergic response and the skin inflammation response are currently being carried out which can lead to identify the genetic factor(s) on 11p14. 
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